Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT01950273 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Follicular

Interventions

DRUG: BI 695500
DRUG: MabThera

Sponsor

Boehringer Ingelheim